Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 5/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069344 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL14198745 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL2069633 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL678187 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL14076891 | 0.88 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL149887 | 0.88 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL2070165 | 0.88 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL12255070 | 0.88 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL133493 | 0.88 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL6092580 | 0.85 | CYP3A4 (0.54) | CYP3A4MAOAMAOBESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | CYP3A4 14/4885MAOA 1190/4885MAOB 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.